bluuebunny/crossref_metadata_2025 huggingface dataset:
Supplementary Materials and Methods, Supplementary Table 1, and Supplementary Figures 1 and 2 from MPT0B098, a Novel Microtubule Inhibitor That Destabilizes the Hypoxia-Inducible Factor-1α mRNA through Decreasing Nuclear–Cytoplasmic Translocation of RNA-Binding Protein HuR
Authors: Cheng Yun-Ching , Liou Jing-Ping , Kuo Ching-Chuan , Lai Wen-Yang , Shih Kuang-Hsing , Chang Chi-Yen , Pan Wen-Yu , Tseng Joseph T. , Chang Jang-Yang
Published: April 2023

PDF - 361KB, Supplementary Materials and Methods; Table S1: Primary Antibodies and secondary antibodies; Figure S1: Effect of MPT0B098 on the organizations of cellular microtubule network; Figure S2: Effect of MPT0B098 on HIF-regulated genes in A549 cells; Figure S3: MPT0B098 inhibits HuR translocation from the nucleus to the cytoplasm in HONE-1 and PC3 cells.
Supplementary Table 1 from Chemogenetic Evaluation of the Mitotic Kinesin CENP-E Reveals a Critical Role in Triple-Negative Breast Cancer
Authors: Kung Pei-Pei , Martinez Ricardo , Zhu Zhou , Zager Michael , Blasina Alessandra , Rymer Isha , Hallin Jill , Xu Meirong , Carroll Christopher , Chionis John , Wells Peter , Kozminski Kirk , Fan Jeffery , Guicherit Oivin , Huang Buwen , Cui Mei , Liu Chaoting , Huang Zhongdong , Sistla Anand , Yang Jennifer , Murray Brion W.
Published: April 2023

PDF - 68K, Broad kinase selectivity analysis of PF-2771.
Supplementary Table 1 from Resveratrol Induces Differentiation Markers Expression in Anaplastic Thyroid Carcinoma via Activation of Notch1 Signaling and Suppresses Cell Growth
Authors: Yu Xiao-Min , Jaskula-Sztul Renata , Ahmed Kamal , Harrison April D. , Kunnimalaiyaan Muthusamy , Chen Herbert
Published: April 2023

PDF file - 44K, Primer sequences for quantitative real-time PCR.
Supplementary Figure 3 from Targeting Multiple Key Signaling Pathways in Melanoma Using Leelamine
Authors: Gowda Raghavendra , Madhunapantula SubbaRao V. , Kuzu Omer F. , Sharma Arati , Robertson Gavin P.
Published: April 2023

PDF - 116K, Pathway or protein expression or activity not regulated by leelamine in UACC 903 melanoma cells.
Legends for supplemental figures and tables from Combination Therapy for KIT-Mutant Mast Cells: Targeting Constitutive NFAT and KIT Activity
Authors: Macleod Alison C. , Klug Lillian R. , Patterson Janice , Griffith Diana J. , Beadling Carol , Town Ajia , Heinrich Michael C.
Published: April 2023

Figure and table legends for supplemental figures 1-4 and supplemental tables 1-3.
Supplementary Figure Legends from A Novel Inhibitor of c-Met and VEGF Receptor Tyrosine Kinases with a Broad Spectrum of In Vivo Antitumor Activities
Authors: Awazu Yoshiko , Nakamura Kazuhide , Mizutani Akio , Kakoi Yuichi , Iwata Hidehisa , Yamasaki Seiji , Miyamoto Naoki , Imamura Shinichi , Miki Hiroshi , Hori Akira
Published: April 2023

PDF File - 102K, Legends for Figures 1-5.
Supplementary Figure 6 from Enhancement of Nab-Paclitaxel Antitumor Activity through Addition of Multitargeting Antiangiogenic Agents in Experimental Pancreatic Cancer
Authors: Awasthi Niranjan , Zhang Changhua , Schwarz Anna M. , Hinz Stefan , Schwarz Margaret A. , Schwarz Roderich E.
Published: April 2023

PDF - 253K, Tumor tissue sections were stained with alpha-SMA antibody and slides were photographed under a fluorescent microscope. alpha-SMA pixel intensity was calculated and represented as bar graph. The data are expressed as the mean (plus or minus) standard deviation.
Supplementary Figure 2 from A Novel Inhibitor of c-Met and VEGF Receptor Tyrosine Kinases with a Broad Spectrum of In Vivo Antitumor Activities
Authors: Awazu Yoshiko , Nakamura Kazuhide , Mizutani Akio , Kakoi Yuichi , Iwata Hidehisa , Yamasaki Seiji , Miyamoto Naoki , Imamura Shinichi , Miki Hiroshi , Hori Akira
Published: April 2023

PDF File - 201K, Inhibition of HGF-induced cell invasion by T-1840383.
Data Supplement from Preclinical Evaluation of Multistep Targeting of Diasialoganglioside GD2 Using an IgG-scFv Bispecific Antibody with High Affinity for GD2 and DOTA Metal Complex
Authors: Cheal Sarah M. , Xu Hong , Guo Hong-fen , Zanzonico Pat B. , Larson Steven M. , Cheung Nai-Kong
Published: April 2023

Supplementary Figure S1. Modeling comparison of two different therapy regimens. Supplementary Figure S2. Positron-emission tomography imaging data for I-124 labeled bispecific antibody in tumor-bearing mice. Supplementary Figure S3. Biodistribution data I-124 labeled bispecific antibody in tumor-bearing mice. Supplementary Tables 1 and 2 are biodistribution data following various pretargeting experiments with the bispecific antibody. Supplementary Table 3 contains hematological and clinical chemistry data from treatment study.
Supplementary Table from Specific Antileukemic Activity of PD0332991, a CDK4/6 Inhibitor, against Philadelphia Chromosome–Positive Lymphoid Leukemia
Authors: Nemoto Atsushi , Saida Satoshi , Kato Itaru , Kikuchi Jiro , Furukawa Yusuke , Maeda Yasuhiro , Akahane Koshi , Honna-Oshiro Hiroko , Goi Kumiko , Kagami Keiko , Kimura Shinya , Sato Yuko , Okabe Seiichi , Niwa Akira , Watanabe Kenichiro , Nakahata Tatsutoshi , Heike Toshio , Sugita Kanji , Inukai Takeshi
Published: April 2023

Supplementary Table S1-S5. Table S1. Characteristics leukemia cell lines. Table S2. List of primary antibodies used for Western blot analysis. Table S3. List of Taqman probe for real-time RT-PCR analysis. Table S4. Sequences of siRNA. Table S5. Sensitivity to PD0332991 of B-precursor cell lines and their gene expression level of components for CDK4/6-cyclin D pathway and gene status of p16.
Supplementary Figure 4 from Metabolomics Identifies Pyrimidine Starvation as the Mechanism of 5-Aminoimidazole-4-Carboxamide-1-β-Riboside-Induced Apoptosis in Multiple Myeloma Cells
Authors: Bardeleben Carolyne , Sharma Sanjai , Reeve Joseph R. , Bassilian Sara , Frost Patrick , Hoang Bao , Shi Yijiang , Lichtenstein Alan
Published: April 2023

PDF file - 145K, AICAr does not activate AMPK in 8226 cells or OPM2 cells and does not inhibit TORC1.
Supplementary Figure 3 from Metabolomics Identifies Pyrimidine Starvation as the Mechanism of 5-Aminoimidazole-4-Carboxamide-1-β-Riboside-Induced Apoptosis in Multiple Myeloma Cells
Authors: Bardeleben Carolyne , Sharma Sanjai , Reeve Joseph R. , Bassilian Sara , Frost Patrick , Hoang Bao , Shi Yijiang , Lichtenstein Alan
Published: April 2023

PDF file - 2312K, Heat map and table of metabolites of significantly altered metabolites in AICAr-treated samples for rapamycin treated samples.
Supplementary Figure Legend from Nuclear Epidermal Growth Factor Receptor Is a Functional Molecular Target in Triple-Negative Breast Cancer
Authors: Brand Toni M. , Iida Mari , Dunn Emily F. , Luthar Neha , Kostopoulos Kellie T. , Corrigan Kelsey L. , Wleklinski Matthew J. , Yang David , Wisinski Kari B. , Salgia Ravi , Wheeler Deric L.
Published: April 2023

PDF - 69K, Legend for Supplementary Figure 1.
Supplementary Figure Legend from Dual Metronomic Chemotherapy with Nab-Paclitaxel and Topotecan Has Potent Antiangiogenic Activity in Ovarian Cancer
Authors: Previs Rebecca A. , Armaiz-Pena Guillermo N. , Lin Yvonne G. , Davis Ashley N. , Pradeep Sunila , Dalton Heather J. , Hansen Jean M. , Merritt William M. , Nick Alpa M. , Langley Robert R. , Coleman Robert L. , Sood Anil K.
Published: April 2023

Hematologic effects of daily metronomic (MET) nab-paclitaxel. White blood count (WBC), hemoglobin, and platelet number were assessed from tumor bearing mice after one, two, and three weeks of treatment.
Supplementary Figure 1 from Dual Metronomic Chemotherapy with Nab-Paclitaxel and Topotecan Has Potent Antiangiogenic Activity in Ovarian Cancer
Authors: Previs Rebecca A. , Armaiz-Pena Guillermo N. , Lin Yvonne G. , Davis Ashley N. , Pradeep Sunila , Dalton Heather J. , Hansen Jean M. , Merritt William M. , Nick Alpa M. , Langley Robert R. , Coleman Robert L. , Sood Anil K.
Published: April 2023

Hematologic effects of daily metronomic (MET) nab-paclitaxel.
Supplementary Figures S1-S4 from The Combination of the PARP Inhibitor Rucaparib and 5FU Is an Effective Strategy for Treating Acute Leukemias
Authors: Falzacappa Maria Vittoria Verga , Ronchini Chiara , Faretta Mario , Iacobucci Ilaria , Di Rorà Andrea Ghelli Luserna , Martinelli Giovanni , Meyer Lüder Hinrich , Debatin Klaus-Michael , Orecchioni Stefania , Bertolini Francesco , Pelicci Pier Giuseppe
Published: April 2023

Supplementary Figures S1-S4. Suppplementary S1: Western Blot analysis o study the effect of the combinatory therapy on DDR Supplementary S2: Evaluation of the percentage of hyper damaged cells among the leukemic compartment Supplementary S3: Cell cycle analysis on OCI-AML2 treated cells Supplementary S4: Model of the mechanism of action of the combinatory therapy PARPi and 5FU
Supplementary Figure 7 from A Novel Human Dynactin-Associated Protein, dynAP, Promotes Activation of Akt, and Ergosterol-Related Compounds Induce dynAP-Dependent Apoptosis of Human Cancer Cells
Authors: Kunoh Tatsuki , Noda Takanori , Koseki Koichi , Sekigawa Masayuki , Takagi Motoki , Shin-ya Kazuo , Goshima Naoki , Iemura Shun-ichiro , Natsume Tohru , Wada Shu-ichi , Mukai Yukio , Ohta Shinji , Sasaki Ryuzo , Mizukami Tamio
Published: April 2023

Supplementary Figure 7 from A Novel Human Dynactin-Associated Protein, dynAP, Promotes Activation of Akt, and Ergosterol-Related Compounds Induce dynAP-Dependent Apoptosis of Human Cancer Cells
Supplementary Figure 6 from A Novel Human Dynactin-Associated Protein, dynAP, Promotes Activation of Akt, and Ergosterol-Related Compounds Induce dynAP-Dependent Apoptosis of Human Cancer Cells
Authors: Kunoh Tatsuki , Noda Takanori , Koseki Koichi , Sekigawa Masayuki , Takagi Motoki , Shin-ya Kazuo , Goshima Naoki , Iemura Shun-ichiro , Natsume Tohru , Wada Shu-ichi , Mukai Yukio , Ohta Shinji , Sasaki Ryuzo , Mizukami Tamio
Published: April 2023

Supplementary Figure 6 from A Novel Human Dynactin-Associated Protein, dynAP, Promotes Activation of Akt, and Ergosterol-Related Compounds Induce dynAP-Dependent Apoptosis of Human Cancer Cells
Supplementary Table 5 from Genome-wide siRNA Screen Identifies the Radiosensitizing Effect of Downregulation of MASTL and FOXM1 in NSCLC
Authors: Nagel Remco , Stigter-van Walsum Marijke , Buijze Marijke , van den Berg Jaap , van der Meulen Ida H. , Hodzic Jasmina , Piersma Sander R. , Pham Thang V. , Jiménez Connie R. , van Beusechem Victor W. , Brakenhoff Ruud H.
Published: April 2023

Supplementary Table 5. Top 10 enriched clusters from phosphoproteomics analyses.
Supplementary Figure 4 from A Novel Human Dynactin-Associated Protein, dynAP, Promotes Activation of Akt, and Ergosterol-Related Compounds Induce dynAP-Dependent Apoptosis of Human Cancer Cells
Authors: Kunoh Tatsuki , Noda Takanori , Koseki Koichi , Sekigawa Masayuki , Takagi Motoki , Shin-ya Kazuo , Goshima Naoki , Iemura Shun-ichiro , Natsume Tohru , Wada Shu-ichi , Mukai Yukio , Ohta Shinji , Sasaki Ryuzo , Mizukami Tamio
Published: April 2023

Supplementary Figure 4 from A Novel Human Dynactin-Associated Protein, dynAP, Promotes Activation of Akt, and Ergosterol-Related Compounds Induce dynAP-Dependent Apoptosis of Human Cancer Cells
Supplementary Methods from Genome-wide siRNA Screen Identifies the Radiosensitizing Effect of Downregulation of MASTL and FOXM1 in NSCLC
Authors: Nagel Remco , Stigter-van Walsum Marijke , Buijze Marijke , van den Berg Jaap , van der Meulen Ida H. , Hodzic Jasmina , Piersma Sander R. , Pham Thang V. , Jiménez Connie R. , van Beusechem Victor W. , Brakenhoff Ruud H.
Published: April 2023

Supplementary Methods. Supplementary methods describing the materials and methods for the phosphoproteomics.
Supplementary Figure 4 from Genome-wide siRNA Screen Identifies the Radiosensitizing Effect of Downregulation of MASTL and FOXM1 in NSCLC
Authors: Nagel Remco , Stigter-van Walsum Marijke , Buijze Marijke , van den Berg Jaap , van der Meulen Ida H. , Hodzic Jasmina , Piersma Sander R. , Pham Thang V. , Jiménez Connie R. , van Beusechem Victor W. , Brakenhoff Ruud H.
Published: April 2023

Supplementary Figure 4. Growth of shMASTL cells and the representation of BUB1 knockdown.
Supplementary Figure 1 from Genome-wide siRNA Screen Identifies the Radiosensitizing Effect of Downregulation of MASTL and FOXM1 in NSCLC
Authors: Nagel Remco , Stigter-van Walsum Marijke , Buijze Marijke , van den Berg Jaap , van der Meulen Ida H. , Hodzic Jasmina , Piersma Sander R. , Pham Thang V. , Jiménez Connie R. , van Beusechem Victor W. , Brakenhoff Ruud H.
Published: April 2023

Supplementary Figure 1. PRKDC knockdown induces radiosensitization.
Supplementary Figure 3 from Novel ATP-Competitive MEK Inhibitor E6201 Is Effective against Vemurafenib-Resistant Melanoma Harboring the MEK1-C121S Mutation in a Preclinical Model
Authors: Narita Yusuke , Okamoto Kiyoshi , Kawada Megumi Ikemori , Takase Kazuma , Minoshima Yukinori , Kodama Kotaro , Iwata Masao , Miyamoto Norimasa , Sawada Kohei
Published: April 2023

PDF - 68K, Effect of vemurafenib, selumetinib, or E6201 on Cyclin D1 expression in (A) exogenous MEK1-C121S-positive or -negative G361 cells and in (B) exogenous MEK1-WT-positive or -negative G361 cells.
Supplementary Table 1 from Marine Sponge Cribrochalina vasculum Compounds Activate Intrinsic Apoptotic Signaling and Inhibit Growth Factor Signaling Cascades in Non–Small Cell Lung Carcinoma
Authors: Zovko Ana , Viktorsson Kristina , Hååg Petra , Kovalerchick Dimitry , Färnegårdh Katarina , Alimonti Andrea , Ilan Micha , Carmeli Shmuel , Lewensohn Rolf
Published: April 2023

Supplementary Table 1: NMR data of (3S)-icos-4E-en-1-yn-3-ol (1).
Supplementary Figures 1 through 9 from Effective Targeting of Estrogen Receptor–Negative Breast Cancers with the Protein Kinase D Inhibitor CRT0066101
Authors: Borges Sahra , Perez Edith A. , Thompson E. Aubrey , Radisky Derek C. , Geiger Xochiquetzal J. , Storz Peter
Published: April 2023

Supplemental Figure S1 shows the differential expression of PKD3 in invasive ductal carcinoma (IDC) by HER2 status; Supplemental Figure S2 shows the status of PKD1, PKD2 and PKD3 expression in invasive breast cancer cell lines; Supplemental Figure S3 depicts the effect of PKD3 knockdown on MDA-MB-231 cell proliferation; Supplemental Figure S4 depicts the effect of PKD3 knockdown on MDA-MB-231 cell migration; Supplemental Figure S5 shows the effect of PKD3 knockdown on tumor growth (A-C)and local invasion (D); Supplemental Figure S6 depicts the effect of CRT0066101 on MDA-MB-231 cell proliferation; Supplemental Figure S7 depicts the effect of CRT0066101 on MDA-MB-231 cell migration; Supplemental Figure S8 shows the impact of PKD2 and PKD3 knockdown alone or in combination on MDA-MB-231 cell migration; and Supplemental Figure S9 depicts the effect of CRT0066101 on tumor growth over time in orthotopic xenografts.
Supplementary Materials and Methods from Marine Sponge Cribrochalina vasculum Compounds Activate Intrinsic Apoptotic Signaling and Inhibit Growth Factor Signaling Cascades in Non–Small Cell Lung Carcinoma
Authors: Zovko Ana , Viktorsson Kristina , Hååg Petra , Kovalerchick Dimitry , Färnegårdh Katarina , Alimonti Andrea , Ilan Micha , Carmeli Shmuel , Lewensohn Rolf
Published: April 2023

Supplementary Materials and Methods and Supplementary Figure Legend
Supplementary Table S1 from Combined Pan-RAF and MEK Inhibition Overcomes Multiple Resistance Mechanisms to Selective RAF Inhibitors
Authors: Whittaker Steven R. , Cowley Glenn S. , Wagner Steve , Luo Flora , Root David E. , Garraway Levi A.
Published: April 2023

RNAi gene enrichment (RIGER) analysis of the primary screen.
Data Supplement from Quinacrine Overcomes Resistance to Erlotinib by Inhibiting FACT, NF-κB, and Cell-Cycle Progression in Non–Small Cell Lung Cancer
Authors: Dermawan Josephine Kam Tai , Gurova Katerina , Pink John , Dowlati Afshin , De Sarmishtha , Narla Goutham , Sharma Neelesh , Stark George R.
Published: April 2023

Supplementary figure S3
Supplementary material and method from Mechanism of Oncogenic Signal Activation by the Novel Fusion Kinase FGFR3–BAIAP2L1
Authors: Nakanishi Yoshito , Akiyama Nukinori , Tsukaguchi Toshiyuki , Fujii Toshihiko , Satoh Yasuko , Ishii Nobuya , Aoki Masahiro
Published: April 2023

Supplementary materials and methods
Supplementary Figure S5 from Mechanism of Oncogenic Signal Activation by the Novel Fusion Kinase FGFR3–BAIAP2L1
Authors: Nakanishi Yoshito , Akiyama Nukinori , Tsukaguchi Toshiyuki , Fujii Toshihiko , Satoh Yasuko , Ishii Nobuya , Aoki Masahiro
Published: April 2023

Comparison of expression level of FGFR3 constructs
Supplementary Figure S2 from Mechanism of Oncogenic Signal Activation by the Novel Fusion Kinase FGFR3–BAIAP2L1
Authors: Nakanishi Yoshito , Akiyama Nukinori , Tsukaguchi Toshiyuki , Fujii Toshihiko , Satoh Yasuko , Ishii Nobuya , Aoki Masahiro
Published: April 2023

Morphological change and ligand independent phosphorylation of FGFR3 in Rat-2 cells or 3T3 cells
Supplementary Figure S1 from Mechanism of Oncogenic Signal Activation by the Novel Fusion Kinase FGFR3–BAIAP2L1
Authors: Nakanishi Yoshito , Akiyama Nukinori , Tsukaguchi Toshiyuki , Fujii Toshihiko , Satoh Yasuko , Ishii Nobuya , Aoki Masahiro
Published: April 2023

Sanger sequence of FGFR3-TACC3 fusion
Supplementary table 4 from Long Noncoding RNA ANRIL Promotes Non–Small Cell Lung Cancer Cell Proliferation and Inhibits Apoptosis by Silencing KLF2 and P21 Expression
Authors: Nie Feng-qi , Sun Ming , Yang Jin-song , Xie Min , Xu Tong-peng , Xia Rui , Liu Yan-wen , Liu Xiang-hua , Zhang Er-bao , Lu Kai-hua , Shu Yong-qian
Published: April 2023

Supplementary table 4. The raw data of ANRIL expression level in all patients
Supplementary table 3 from Long Noncoding RNA ANRIL Promotes Non–Small Cell Lung Cancer Cell Proliferation and Inhibits Apoptosis by Silencing KLF2 and P21 Expression
Authors: Nie Feng-qi , Sun Ming , Yang Jin-song , Xie Min , Xu Tong-peng , Xia Rui , Liu Yan-wen , Liu Xiang-hua , Zhang Er-bao , Lu Kai-hua , Shu Yong-qian
Published: April 2023

Supplementary table 3. Sequence of primers and siRNA
Supplementary table 1 from Long Noncoding RNA ANRIL Promotes Non–Small Cell Lung Cancer Cell Proliferation and Inhibits Apoptosis by Silencing KLF2 and P21 Expression
Authors: Nie Feng-qi , Sun Ming , Yang Jin-song , Xie Min , Xu Tong-peng , Xia Rui , Liu Yan-wen , Liu Xiang-hua , Zhang Er-bao , Lu Kai-hua , Shu Yong-qian
Published: April 2023

Supplementary table 1. Univariate and multivariate analysis of progression-free survival in NSCLC patients (n=68)
Supplementary Figure 1 from Delineating the mTOR Kinase Pathway Using a Dual TORC1/2 Inhibitor, AZD8055, in Multiple Myeloma
Authors: Cirstea Diana , Santo Loredana , Hideshima Teru , Eda Homare , Mishima Yuko , Nemani Neeharika , Mahindra Anuj , Yee Andrew , Gorgun Gullu , Hu Yiguo , Ohguchi Hiroto , Suzuki Rikio , Cottini Francesca , Guichard Sylvie M. , Anderson Kenneth C. , Raje Noopur
Published: April 2023

Supplementary Figure 1: U266 cells were transiently transfected with 500 nM of small interfering RNA (siRNA) SMARTpool for IGF1R or nonspecific control duplexes (pool of four; Thermo Scientific Dharmacon) using the Cell Line Nucleofector Kit V Solution (Amaxa Biosystems, Cologne, Germany), program X-005. After collection, cells were plated in a 96 well plate (20000 cells/well) and 72 h MTT viability assay was performed. Western blot analysis 72 hr after transfection shows a decrease in IGF1R expression in the U266 cell line ( lower panel). For the MTT assay, control cells (transfected with non specific control) were treated with and without AZD8055 100 nM, 66% decrease in viability was observed in presence of AZD8055. Transfected cells (IGF1R knock out cells) were cultured with and without AZD8055 100 nM. IGF1R knockout cells show 39% decrease in viability compared to scramble control and the combination of IGF1R knock out and AZD8055 100 nM show a 78% decrease in viability compared to scramble control. This finding suggests that IGF1R knockout sensitizes to AZD8055 inhibition similar to IGF1R antibody.
Supplementary Figures 1 through 11 and Supplementary Figure Legends from Preclinical Evaluation of a Novel RXR Agonist for the Treatment of Neuroblastoma
Authors: Waters Alicia M. , Stewart Jerry E. , Atigadda Venkatram R. , Mroczek-Musulman Elizabeth , Muccio Donald D. , Grubbs Clinton J. , Beierle Elizabeth A.
Published: April 2023

Figure S1 / S2. UAB30 activated caspase 3. Figure S3. UAB30 increased nestin protein. Figure S4 / S5. UAB30 decreased neuroblastoma cellular proliferation. Figure S6 / S7. UAB30 did not alter expression or phosphorylation of ERK1/2 or AKT. Figure S8 / S9. UAB30 did not alter p53 expression. Figure S10. UAB30 did not affect MYCN expression. Figure S11. Tumor weight to animal weight ratio.
Supplementary Table S1 from Triple-Negative Breast Cancer Patients Treated at MD Anderson Cancer Center in Phase I Trials: Improved Outcomes with Combination Chemotherapy and Targeted Agents
Authors: Ganesan Prasanth , Moulder Stacy , Lee J. Jack , Janku Filip , Valero Vicente , Zinner Ralph G. , Naing Aung , Fu Siqing , Tsimberidou Apostolia M. , Hong David , Stephen Bettzy , Stephens Philip , Yelensky Roman , Meric-Bernstam Funda , Kurzrock Razelle , Wheler Jennifer J.
Published: April 2023

Supplementary Table S1. Description of targeted therapies used in various phase I trials involved in various phase I trials (n=106)
Supplementary Information from Cambogin Induces Caspase-Independent Apoptosis through the ROS/JNK Pathway and Epigenetic Regulation in Breast Cancer Cells
Authors: Shen Kaikai , Xie Jianling , Wang Hua , Zhang Hong , Yu Mengyuan , Lu Fangfang , Tan Hongsheng , Xu Hongxi
Published: April 2023

Supplementary Information. Supplementary Material & Methods; supplementary figure legends; supplementary table 1 and reference.
Supplemental Figure 3 from Small Molecule Inhibition of MERTK Is Efficacious in Non–Small Cell Lung Cancer Models Independent of Driver Oncogene Status
Authors: Cummings Christopher T. , Zhang Weihe , Davies Kurtis D. , Kirkpatrick Gregory D. , Zhang Dehui , DeRyckere Deborah , Wang Xiaodong , Frye Stephen V. , Earp H. Shelton , Graham Douglas K.
Published: April 2023

Supplemental Figure 3: pMERTK and MERTK are not Predictive of Sensitivity to UNC2025.
Supplementary Figure 6 from Cambogin Induces Caspase-Independent Apoptosis through the ROS/JNK Pathway and Epigenetic Regulation in Breast Cancer Cells
Authors: Shen Kaikai , Xie Jianling , Wang Hua , Zhang Hong , Yu Mengyuan , Lu Fangfang , Tan Hongsheng , Xu Hongxi
Published: April 2023

Supplementary Figure 6. Related to Fig.5, in MDA-MB-468 and SK-BR-3 cells, similar to MCF-7 cells tested in Fig. 5, JNK/SAPK signaling pathway is also activated upon cambogin treatment, and this is responsible for cambogin-induced cell death.
Supplementary Figure 4 from Cambogin Induces Caspase-Independent Apoptosis through the ROS/JNK Pathway and Epigenetic Regulation in Breast Cancer Cells
Authors: Shen Kaikai , Xie Jianling , Wang Hua , Zhang Hong , Yu Mengyuan , Lu Fangfang , Tan Hongsheng , Xu Hongxi
Published: April 2023

Supplementary Figure 4. We studied the content of GSSG, TGSH and GSH in response to cambogin in MCF-7 cells. GSSG (oxidized glutathione) levels were elevated upon cambogin treatment whereas GSH levels were decreased from 4 to 24 h, which indicates possible ROS production in cambogin-treated MCF-7 cells.
Supplemental Figure legends from Targeting the Nuclear Import Receptor Kpnβ1 as an Anticancer Therapeutic
Authors: van der Watt Pauline J. , Chi Alicia , Stelma Tamara , Stowell Catherine , Strydom Erin , Carden Sarah , Angus Liselotte , Hadley Kate , Lang Dirk , Wei Wei , Birrer Michael J. , Trent John O. , Leaner Virna D.
Published: April 2023

Supplemental Figure Legends
Supplemental Table 2 from MCL-1 Is a Key Determinant of Breast Cancer Cell Survival: Validation of MCL-1 Dependency Utilizing a Highly Selective Small Molecule Inhibitor
Authors: Xiao Yu , Nimmer Paul , Sheppard George S. , Bruncko Milan , Hessler Paul , Lu Xin , Roberts-Rapp Lisa , Pappano William N. , Elmore Steven W. , Souers Andrew J. , Leverson Joel D. , Phillips Darren C.
Published: April 2023

Supplemental Table 2: Navitoclax EC50s in breast cancer cell lines in the presence or absence of MCL-1 siRNA.
Supplemental Table 1 from MCL-1 Is a Key Determinant of Breast Cancer Cell Survival: Validation of MCL-1 Dependency Utilizing a Highly Selective Small Molecule Inhibitor
Authors: Xiao Yu , Nimmer Paul , Sheppard George S. , Bruncko Milan , Hessler Paul , Lu Xin , Roberts-Rapp Lisa , Pappano William N. , Elmore Steven W. , Souers Andrew J. , Leverson Joel D. , Phillips Darren C.
Published: April 2023

Supplemental Table 1: Viability of breast cancer cell lines treated with PBS, scrambled siRNA (Sc; 20nMol) or MCL-1 siRNA (20nMol) for 72hrs compared to non-treated cells with associated genomic info.
Figure S3 from Berberine Induces Senescence of Human Glioblastoma Cells by Downregulating the EGFR–MEK–ERK Signaling Pathway
Authors: Liu Qiao , Xu Xiuhua , Zhao Minnan , Wei Zhao , Li Xi , Zhang Xiyu , Liu Zhaojian , Gong Yaoqin , Shao Changshun
Published: April 2023

Figure S3. EGFR inhibitor fails to induce apoptosis in U87 cells
Supplementary Figures S1 and S2 from Small Molecule Inhibitor YM155-Mediated Activation of Death Receptor 5 Is Crucial for Chemotherapy-Induced Apoptosis in Pancreatic Carcinoma
Authors: Zhao Xiangxuan , Puszyk William M. , Lu Zaiming , Ostrov David A. , George Thomas J. , Robertson Keith D. , Liu Chen
Published: April 2023

Figure S1 shows the effect of YM155 on Panc-1 cells as evidenced by hoechst staining, DNA ladder assay and western blotting analysis of caspases 3, 8 as well as BID and PARP. Figure S2 shows the effect of YM155 on another pancreatic cell line PC-3 as evidenced by hoechst staining and western blotting analysis of survivin and DR5 expression.
Supplementary Figure S5 from A Novel Photodynamic Therapy Targeting Cancer Cells and Tumor-Associated Macrophages
Authors: Hayashi Noriyuki , Kataoka Hiromi , Yano Shigenobu , Tanaka Mamoru , Moriwaki Kazuhiro , Akashi Haruo , Suzuki Shugo , Mori Yoshinori , Kubota Eiji , Tanida Satoshi , Takahashi Satoru , Joh Takashi
Published: April 2023

M-chlorin and G-chlorin accumulation in tumor regions.
Supplementary Figure S3 from A Novel Photodynamic Therapy Targeting Cancer Cells and Tumor-Associated Macrophages
Authors: Hayashi Noriyuki , Kataoka Hiromi , Yano Shigenobu , Tanaka Mamoru , Moriwaki Kazuhiro , Akashi Haruo , Suzuki Shugo , Mori Yoshinori , Kubota Eiji , Tanida Satoshi , Takahashi Satoru , Joh Takashi
Published: April 2023

Expression of mannose receptor family members in cell lines.
Supplementary Figure Legends and Supplementary Figures 1 through 4 from A Novel Therapeutic Strategy to Rescue the Immune Effector Function of Proteolytically Inactivated Cancer Therapeutic Antibodies
Authors: Fan Xuejun , Brezski Randall J. , Deng Hui , Dhupkar Pooja M. , Shi Yun , Gonzalez Anneliese , Zhang Songlin , Rycyzyn Michael , Strohl William R. , Jordan Robert E. , Zhang Ningyan , An Zhiqiang
Published: April 2023

Figure S1: IdeS expression in BT474 breast cancer cells Figure S2: Detection of MMPs in cancer cell lysates and culture supernatant Figure S3: scIgG-T was not in the SKBR-3 cell culture medium Figure S4: Detection of immune cells infiltration in mice by flow cytometry.
Supplementary Figure S3 from Preclinical Pharmacokinetics, Tolerability, and Pharmacodynamics of Metuzumab, a Novel CD147 Human–Mouse Chimeric and Glycoengineered Antibody
Authors: Zhang Zheng , Zhang Yang , Sun Qian , Feng Fei , Huhe Muren , Mi Li , Chen Zhinan
Published: April 2023

Supplementary Figure S3. CD147 expression levels in A549 and NCI-H520 cells were determined by flow cytometry using a FITC-labeled mouse anti-human CD147 primary mAb (Becton, Dickinson and Company) and a mouse IgG1 mAb as an isotype control. The results shown are mean values {plus minus} S.D. and are representative of 3 independent experiments.
Supplementary Figure Legends from Preclinical Pharmacokinetics, Tolerability, and Pharmacodynamics of Metuzumab, a Novel CD147 Human–Mouse Chimeric and Glycoengineered Antibody
Authors: Zhang Zheng , Zhang Yang , Sun Qian , Feng Fei , Huhe Muren , Mi Li , Chen Zhinan
Published: April 2023

Supplementary Figure Legends
Supplementary Table S3 from Selective Inhibition of SIN3 Corepressor with Avermectins as a Novel Therapeutic Strategy in Triple-Negative Breast Cancer
Authors: Kwon Yeon-Jin , Petrie Kevin , Leibovitch Boris A. , Zeng Lei , Mezei Mihaly , Howell Louise , Gil Veronica , Christova Rossitza , Bansal Nidhi , Yang Shuai , Sharma Rajal , Ariztia Edgardo V. , Frankum Jessica , Brough Rachel , Sbirkov Yordan , Ashworth Alan , Lord Christopher J. , Zelent Arthur , Farias Eduardo , Zhou Ming-Ming , Waxman Samuel
Published: April 2023

Supplementary Table S3. Ingenuity Canonical Pathways modulated by selamectin treatment
Supplementary Table S6 from Identification of Kinase Inhibitor Targets in the Lung Cancer Microenvironment by Chemical and Phosphoproteomics
Authors: Gridling Manuela , Ficarro Scott B. , Breitwieser Florian P. , Song Lanxi , Parapatics Katja , Colinge Jacques , Haura Eric B. , Marto Jarrod A. , Superti-Furga Giulio , Bennett Keiryn L. , Rix Uwe
Published: April 2023

Table S6. Detailed peptide information for chemical proteomics experiments with c-dasatinib and c-sunitinib in xenograft samples of H292 and of H23 cell lines.
Supplementary Figure 3 from SRT1720 Induces Lysosomal-Dependent Cell Death of Breast Cancer Cells
Authors: Lahusen Tyler J. , Deng Chu-Xia
Published: April 2023

Supplementary Figure 3. Cell viability of MDA-MB-231 cells treated with SRT1720 and the pan-sirtuin inhibitor, nicotinamide
Supplementary Figure S1 from Identification of Kinase Inhibitor Targets in the Lung Cancer Microenvironment by Chemical and Phosphoproteomics
Authors: Gridling Manuela , Ficarro Scott B. , Breitwieser Florian P. , Song Lanxi , Parapatics Katja , Colinge Jacques , Haura Eric B. , Marto Jarrod A. , Superti-Furga Giulio , Bennett Keiryn L. , Rix Uwe
Published: April 2023

Figure S1. Cross-docking of sunitinib and dasatinib in NQO2 and PDXK.
Supplementary Figure 1 from Pazopanib, a Novel Multitargeted Kinase Inhibitor, Shows Potent In Vitro Antitumor Activity in Gastric Cancer Cell Lines with FGFR2 Amplification
Authors: Kim Seung Tae , Jang Hye-Lim , Lee Su Jin , Lee Jeeyun , Choi Yoon-La , Kim Kyoung-Mee , Cho Jeonghee , Park Se Hoon , Park Young Suk , Lim Ho Yeong , Yashiro Masakazu , Kang Won Ki , Park Joon Oh
Published: April 2023

Supplementary Figure 1: FGFR2 probe for FISH
Supplementary Table 1 from An Antimesothelin-Monomethyl Auristatin E Conjugate with Potent Antitumor Activity in Ovarian, Pancreatic, and Mesothelioma Models
Authors: Scales Suzie J. , Gupta Nidhi , Pacheco Glenn , Firestein Ron , French Dorothy M. , Koeppen Hartmut , Rangell Linda , Barry-Hamilton Vivian , Luis Elizabeth , Chuh Josefa , Zhang Yin , Ingle Gladys S. , Fourie-O'Donohue Aimee , Kozak Katherine R. , Ross Sarajane , Dennis Mark S. , Spencer Susan D.
Published: April 2023

Supplementary Table 1: Summary of 5B2 anti-mesothelin IHC literature and TMA details.
Supplementary Fig 4 from Sunitinib Dose Escalation Overcomes Transient Resistance in Clear Cell Renal Cell Carcinoma and Is Associated with Epigenetic Modifications
Authors: Adelaiye Remi , Ciamporcero Eric , Miles Kiersten Marie , Sotomayor Paula , Bard Jonathan , Tsompana Maria , Conroy Dylan , Shen Li , Ramakrishnan Swathi , Ku Sheng-Yu , Orillion Ashley , Prey Joshua , Fetterly Gerald , Buck Michael , Chintala Sreenivasulu , Bjarnason Georg A. , Pili Roberto
Published: April 2023

Supplementary Fig 4. Intratumoral and plasma sunitinib concentrations
Supplementary Figure 3 from An Antimesothelin-Monomethyl Auristatin E Conjugate with Potent Antitumor Activity in Ovarian, Pancreatic, and Mesothelioma Models
Authors: Scales Suzie J. , Gupta Nidhi , Pacheco Glenn , Firestein Ron , French Dorothy M. , Koeppen Hartmut , Rangell Linda , Barry-Hamilton Vivian , Luis Elizabeth , Chuh Josefa , Zhang Yin , Ingle Gladys S. , Fourie-O'Donohue Aimee , Kozak Katherine R. , Ross Sarajane , Dennis Mark S. , Spencer Susan D.
Published: April 2023

Supplementary Figure 3: In vivo efficacy data from Figure 6 replotted as mean tumor volumes {plus minus} SEM.
Supplementary Fig 3 from Sunitinib Dose Escalation Overcomes Transient Resistance in Clear Cell Renal Cell Carcinoma and Is Associated with Epigenetic Modifications
Authors: Adelaiye Remi , Ciamporcero Eric , Miles Kiersten Marie , Sotomayor Paula , Bard Jonathan , Tsompana Maria , Conroy Dylan , Shen Li , Ramakrishnan Swathi , Ku Sheng-Yu , Orillion Ashley , Prey Joshua , Fetterly Gerald , Buck Michael , Chintala Sreenivasulu , Bjarnason Georg A. , Pili Roberto
Published: April 2023

Supplementary Fig 3. Liver histology and body weights of mice on sunitinib dose escalation.
Supplementary Figure 2 from An Antimesothelin-Monomethyl Auristatin E Conjugate with Potent Antitumor Activity in Ovarian, Pancreatic, and Mesothelioma Models
Authors: Scales Suzie J. , Gupta Nidhi , Pacheco Glenn , Firestein Ron , French Dorothy M. , Koeppen Hartmut , Rangell Linda , Barry-Hamilton Vivian , Luis Elizabeth , Chuh Josefa , Zhang Yin , Ingle Gladys S. , Fourie-O'Donohue Aimee , Kozak Katherine R. , Ross Sarajane , Dennis Mark S. , Spencer Susan D.
Published: April 2023

Supplementary Figure 2: IHC validation of anti-mesothelin antibody SP74.
Supplementary Movie SM4 from Tumor-Penetrating iRGD Peptide Inhibits Metastasis
Authors: Sugahara Kazuki N. , Braun Gary B. , de Mendoza Tatiana Hurtado , Kotamraju Venkata Ramana , French Randall P. , Lowy Andrew M. , Teesalu Tambet , Ruoslahti Erkki
Published: April 2023

Supplementary Movie SM4. Tumor cell migration on CRGDC silver nanoparticles
Supplementary Figure 2 from Novel Selective Estrogen Mimics for the Treatment of Tamoxifen-Resistant Breast Cancer
Authors: Molloy Mary Ellen , White Bethany E. Perez , Gherezghiher Teshome , Michalsen Bradley T. , Xiong Rui , Patel Hitisha , Zhao Huiping , Maximov Philipp Y. , Jordan V. Craig , Thatcher Gregory R.J. , Tonetti Debra A.
Published: April 2023

Supplementary Figure 2: (A) Reconstructed ion chromatogram for the MRM transition m/z 241 to 208 of standard BTC (100ng/mL); (B) Reconstructed ion chromatogram for the MRM transition m/z 709 to 171 of standard DansylBTC (100ng/ml).
Supplementary Materials and Methods from The Fibroblast Growth Factor Receptor Genetic Status as a Potential Predictor of the Sensitivity to CH5183284/Debio 1347, a Novel Selective FGFR Inhibitor
Authors: Nakanishi Yoshito , Akiyama Nukinori , Tsukaguchi Toshiyuki , Fujii Toshihiko , Sakata Kiyoaki , Sase Hitoshi , Isobe Takehito , Morikami Kenji , Shindoh Hidetoshi , Mio Toshiyuki , Ebiike Hirosato , Taka Naoki , Aoki Yuko , Ishii Nobuya
Published: April 2023

Supplementary Materials and Methods from The Fibroblast Growth Factor Receptor Genetic Status as a Potential Predictor of the Sensitivity to CH5183284/Debio 1347, a Novel Selective FGFR Inhibitor
Supplemental Table 1 from Tumor-Penetrating iRGD Peptide Inhibits Metastasis
Authors: Sugahara Kazuki N. , Braun Gary B. , de Mendoza Tatiana Hurtado , Kotamraju Venkata Ramana , French Randall P. , Lowy Andrew M. , Teesalu Tambet , Ruoslahti Erkki
Published: April 2023

Supplemental Table 1. Summary of statistical analysis
Data Supplement from Activation of Nrf2 Pathways Correlates with Resistance of NSCLC Cell Lines to CBP501 In Vitro
Authors: Mine Naoki , Yamamoto Sayaka , Kufe Donald W. , Von Hoff Daniel D. , Kawabe Takumi
Published: April 2023

Supplemental Table 1. Keap1 mutation in NSCLC cell lines. Supplemental Figure 1. Comparative analysis of individual gene expression as in CBP501 insensitive cell lines or the CBP501 sensitive cell lines from figure 2. Black bars indicate the average values of expression in CBP501 insensitive cell lines. Red bars indicate the average values of expression in CBP501 sensitive cell lines. Supplemental Figure 2. (A) Immunocytochemistry for AKR1C1 in NSCLCs. Left panels show AKR1C1 in a pseudo-color of green. Middle panels show Hoechst in a pseudo-color of red. Right panels show the merged images. Scale bar indicates 100mm. (B) Quantification of AKR1C1 intensities from A (n=5). Supplemental Figure 3. (A) Immunocytochemistry for AKR1B10 in NSCLCs. Left panels show AKR1B10 in a pseudo-color of green. Middle panels show Hoechst dye in a pseudo-color of red. Right panels show the merged images. Scale bar indicates 100mm. (B) Quantification of AKR1B10 intensities from A (n=5).
Supplementary Tables S5, S6, S7, S8 from Enhanced Targeting of the EGFR Network with MM-151, an Oligoclonal Anti-EGFR Antibody Therapeutic
Authors: Kearns Jeffrey D. , Bukhalid Raghida , Sevecka Mark , Tan Gege , Gerami-Moayed Nastaran , Werner Shannon L. , Kohli Neeraj , Burenkova Olga , Sloss Callum M. , King Anne M. , Fitzgerald Jonathan B. , Nielsen Ulrik B. , Wolf Beni B.
Published: April 2023

Supplementary Tables S5, S6, S7, S8. mRNA expression data for EGFR ligands as measured by RNAseq from The Cancer Genome Atlas (TCGA) across 14 cancer indications or by RT-qPCR of colorectal cancer FFPE samples. Table S5: Summary of TCGA datasets included in the analysis. Table S6: Raw and normalized expression data from TCGA. Table S7: EGFR ligand expression measured by RT-qPCR on commercially-obtained colorectal cancer FFPE samples. Table S8: Pairwise correlations of EGFR ligands across four TCGA indications.
Supplementary Tables S2, S3, S4 from Enhanced Targeting of the EGFR Network with MM-151, an Oligoclonal Anti-EGFR Antibody Therapeutic
Authors: Kearns Jeffrey D. , Bukhalid Raghida , Sevecka Mark , Tan Gege , Gerami-Moayed Nastaran , Werner Shannon L. , Kohli Neeraj , Burenkova Olga , Sloss Callum M. , King Anne M. , Fitzgerald Jonathan B. , Nielsen Ulrik B. , Wolf Beni B.
Published: April 2023

Supplementary Tables S2, S3, S4. Structure of the computational model of multiple ligand antagonists: species (Table S2), parameters (Table S3), and Reactions (Table S4).
Supplementary Figure Legends, Tables 1 - 3 from Loss of Tuberous Sclerosis Complex 2 (TSC2) Is Frequent in Hepatocellular Carcinoma and Predicts Response to mTORC1 Inhibitor Everolimus
Authors: Huynh Hung , Hao Huai-Xiang , Chan Stephen L. , Chen David , Ong Richard , Soo Khee Chee , Pochanard Panisa , Yang David , Ruddy David , Liu Manway , Derti Adnan , Balak Marissa N. , Palmer Michael R. , Wang Yan , Lee Benjamin H. , Sellami Dalila , Zhu Andrew X. , Schlegel Robert , Huang Alan
Published: April 2023

Supplementary Table 1. Quantification of phospho-protein levels in Figure 1B. Supplementary Table 2. Everolimus IC50 and growth inhibition at 1uM in HCC cell lines. Supplementary Table 3. Quantification of phospho-protein levels in Figure 2A.
Supplementary Tables 7 through 9 from miR200c Attenuates P-gp–Mediated MDR and Metastasis by Targeting JNK2/c-Jun Signaling Pathway in Colorectal Cancer
Authors: Sui Hua , Cai Guo-Xiang , Pan Shu-Fang , Deng Wan-Li , Wang Yu-Wei , Chen Zhe-Sheng , Cai San-Jun , Zhu Hui-Rong , Li Qi
Published: April 2023

Supplementary Tables 7 through 9: PCR primers and gene sequences and Results of orthotopic implantation of tumor xenografts demonstrating the primary invasion and metastases based on histologic evaluation.
Supplementary Tables 1 through 4 from miR200c Attenuates P-gp–Mediated MDR and Metastasis by Targeting JNK2/c-Jun Signaling Pathway in Colorectal Cancer
Authors: Sui Hua , Cai Guo-Xiang , Pan Shu-Fang , Deng Wan-Li , Wang Yu-Wei , Chen Zhe-Sheng , Cai San-Jun , Zhu Hui-Rong , Li Qi
Published: April 2023

Supplementary Tables 1 through 4: Resistance to chemotherapeutic drugs in HCT8/V and HCT116/MDR cells.
Supplementary Figure Legends and Supplementary Figures 1 and 2 from Direct Binding of Arsenic Trioxide to AMPK and Generation of Inhibitory Effects on Acute Myeloid Leukemia Precursors
Authors: Beauchamp Elspeth M. , Kosciuczuk Ewa M. , Serrano Ruth , Nanavati Dhaval , Swindell Elden P. , Viollet Benoit , O'Halloran Thomas V. , Altman Jessica K. , Platanias Leonidas C.
Published: April 2023

Supplementary Figure Legends. Supplementary Figure 1: Targeted disruption of AMPKα1/2 does not affect arsenicinducible phosphorylation of AKT at Ser473. Supplementary Figure 2: As- Biotin binds to AMPKα as measured by mass spectroscopy
Supplementary Figure 3 from Efficacy of RG7787, a Next-Generation Mesothelin-Targeted Immunotoxin, against Triple-Negative Breast and Gastric Cancers
Authors: Alewine Christine , Xiang Laiman , Yamori Takao , Niederfellner Gerhard , Bosslet Klaus , Pastan Ira
Published: April 2023

Supplementary Figure 3. Graph showing growth of xenografted MKN28 gastric tumors following treatment with paclitaxel alone or in combination with RG7787 over a 60 day time course.
Supplementary Fig. 2 from Small Molecule Inhibition of MDM2–p53 Interaction Augments Radiation Response in Human Tumors
Authors: Werner Lauryn R. , Huang Shyhmin , Francis David M. , Armstrong Eric A. , Ma Fang , Li Chunrong , Iyer Gopal , Canon Jude , Harari Paul M.
Published: April 2023

Supplementary Fig. 2. Effect of AMG 232 on DNA damage repair signaling and Î³H2AX expression.
Supplemental Figure 1 from Heregulin–ErbB3-Driven Tumor Growth Persists in PI3 Kinase Mutant Cancer Cells
Authors: Yarar Defne , Lahdenranta Johanna , Kubasek William , Nielsen Ulrik B. , MacBeath Gavin
Published: April 2023

Western blots and quantification of (pERK, pS6RP-S235-236) of lysates generated from engineered cells.
Supplementary Figures from Dual Targeting of Hypoxia and Homologous Recombination Repair Dysfunction in Triple-Negative Breast Cancer
Authors: Hunter Francis W. , Hsu Huai-Ling , Su Jiechuang , Pullen Susan M. , Wilson William R. , Wang Jingli
Published: April 2023

Supplementary Figures. Supplementary Figures including correlations of HAP sensitivity between cell lines, development and characterisation of doxycycline-inducible shRNA cell lines, and effect of BRCA2 knockout on radiation sensitivity of DLD-1 tumor xenografts
Supplementary Figure 6 from A687V EZH2 Is a Driver of Histone H3 Lysine 27 (H3K27) Hypertrimethylation
Authors: Ott Heidi M. , Graves Alan P. , Pappalardi Melissa B. , Huddleston Michael , Halsey Wendy S. , Hughes Ashley M. , Groy Arthur , Dul Edward , Jiang Yong , Bai Yuchen , Annan Roland , Verma Sharad K. , Knight Steven D. , Kruger Ryan G. , Dhanak Dashyant , Schwartz Benjamin , Tummino Peter J. , Creasy Caretha L. , McCabe Michael T.
Published: April 2023

Supplementary Figure 6: Gene Set Enrichment Analysis (GSEA) for SUP-B8 cells treated with GSK126
Supplemental Figure 6 from Histone Deacetylase Inhibitor Entinostat Inhibits Tumor-Initiating Cells in Triple-Negative Breast Cancer Cells
Authors: Schech Amanda , Kazi Armina , Yu Stephen , Shah Preeti , Sabnis Gauri
Published: April 2023

Supplemental Figure 6. Effect of TGF-ÃŸ on cellular morphology of MCF-10A cells
Supplemental Figures S4 - S5 from Tissue Penetration and Activity of Camptothecins in Solid Tumor Xenografts
Authors: Kyle Alastair H. , Baker Jennifer H.E. , Gandolfo Maria-Jose , Reinsberg Stefan A. , Minchinton Andrew I.
Published: April 2023

Supplemental FIGS S4 - S5 - Summary of vascular density, vascular patentcy and tissue hypoxia measurements following camptothecin treatment.
Supplementary Figure S10 from Inhibition of p70S6K1 Activation by Pdcd4 Overcomes the Resistance to an IGF-1R/IR Inhibitor in Colon Carcinoma Cells
Authors: Zhang Yan , Wang Qing , Chen Li , Yang Hsin-Sheng
Published: April 2023

Supplementary Figure S10: Semi-quantitative analyses of the Western blot result of SW480 cells in Fig. 5E
Supplementary Figure List from Radiation Protection of the Gastrointestinal Tract and Growth Inhibition of Prostate Cancer Xenografts by a Single Compound
Authors: Alexeev Vitali , Lash Elizabeth , Aguillard April , Corsini Laura , Bitterman Avi , Ward Keith , Dicker Adam P. , Linnenbach Alban , Rodeck Ulrich
Published: April 2023

List of Supplementary Figures
Supplementary Figure 4 from Radiation Protection of the Gastrointestinal Tract and Growth Inhibition of Prostate Cancer Xenografts by a Single Compound
Authors: Alexeev Vitali , Lash Elizabeth , Aguillard April , Corsini Laura , Bitterman Avi , Ward Keith , Dicker Adam P. , Linnenbach Alban , Rodeck Ulrich
Published: April 2023

Supplementary Figure 4: Effects of RTA 408 on radiation sensitivity of prostate cancer cell lines as determined by clonogenic survival assays. Cells were treated at 24 and 1 h with RTA 408 prior to IR exposure as indicated. Differences between curves were analyzed by two-way ANOVA, designating drug treatment and IR as variables. P value summaries of pair-wise comparisons between drug and vehicle treatment curves are shown.
Supplementary Figure 5 from CDK1-Mediated SIRT3 Activation Enhances Mitochondrial Function and Tumor Radioresistance
Authors: Liu Rui , Fan Ming , Candas Demet , Qin Lili , Zhang Xiaodi , Eldridge Angela , Zou June X. , Zhang Tieqiao , Juma Shuaib , Jin Cuihong , Li Robert F. , Perks Julian , Sun Lun-Quan , Vaughan Andrew T.M. , Hai Chun-Xu , Gius David R. , Li Jian Jian
Published: April 2023

Clonogenic survival ability of HCT116 cells via MnSOD activation
Data Supplement from Antiproliferative Effects of CDK4/6 Inhibition in CDK4-Amplified Human Liposarcoma In Vitro and In Vivo
Authors: Zhang Yi-Xiang , Sicinska Ewa , Czaplinski Jeffrey T. , Remillard Stephen P. , Moss Samuel , Wang Yuchuan , Brain Christopher , Loo Alice , Snyder Eric L. , Demetri George D. , Kim Sunkyu , Kung Andrew L. , Wagner Andrew J.
Published: April 2023

Effects of LEE011 treatment on mice body weight
Supplementary Figure 1 from CDK1-Mediated SIRT3 Activation Enhances Mitochondrial Function and Tumor Radioresistance
Authors: Liu Rui , Fan Ming , Candas Demet , Qin Lili , Zhang Xiaodi , Eldridge Angela , Zou June X. , Zhang Tieqiao , Juma Shuaib , Jin Cuihong , Li Robert F. , Perks Julian , Sun Lun-Quan , Vaughan Andrew T.M. , Hai Chun-Xu , Gius David R. , Li Jian Jian
Published: April 2023

Western blot analysis of SIRT3 and acetylated mitochondrial proteins of human breast cancer MDA-231 cells and glioblastoma U87 cells
Figure S1 from AT2R Gene Delivered by Condensed Polylysine Complexes Attenuates Lewis Lung Carcinoma after Intravenous Injection or Intratracheal Spray
Authors: Alhakamy Nabil A. , Ishiguro Susumu , Uppalapati Deepthi , Berkland Cory J. , Tamura Masaaki
Published: April 2023

Figure S1. The transfection efficiencies of the pLUC-Ca2+ and the K9-pLUC-Ca2+ complexes in various cell lines designated in the figure were determined in the presence of 38 mM calcium chloride at an N/P ratio 10. RLUs refer to relative light units. Results are presented as mean {plus minus} SD (n = 4). ***, P < 0.0005 determined by Student t test.
Supplementary Table S1 from TP53 Alterations Correlate with Response to VEGF/VEGFR Inhibitors: Implications for Targeted Therapeutics
Authors: Wheler Jennifer J. , Janku Filip , Naing Aung , Li Yali , Stephen Bettzy , Zinner Ralph , Subbiah Vivek , Fu Siqing , Karp Daniel , Falchook Gerald S. , Tsimberidou Apostolia M. , Piha-Paul Sarina , Anderson Roosevelt , Ke Danxia , Miller Vincent , Yelensky Roman , Lee J. Jack , Hong David , Kurzrock Razelle
Published: April 2023

Agents targeting VEGF or VEGFR used to treat patientsa
Supplementary Materials and Methods from A Novel RAF Kinase Inhibitor with DFG-Out–Binding Mode: High Efficacy in BRAF-Mutant Tumor Xenograft Models in the Absence of Normal Tissue Hyperproliferation
Authors: Waizenegger Irene C. , Baum Anke , Steurer Steffen , Stadtmüller Heinz , Bader Gerd , Schaaf Otmar , Garin-Chesa Pilar , Schlattl Andreas , Schweifer Norbert , Haslinger Christian , Colbatzky Florian , Mousa Sien , Kalkuhl Arno , Kraut Norbert , Adolf Günther R.
Published: April 2023

Protocols for data shown in the Supplement
Supplementary Figure Legends from A Novel RAF Kinase Inhibitor with DFG-Out–Binding Mode: High Efficacy in BRAF-Mutant Tumor Xenograft Models in the Absence of Normal Tissue Hyperproliferation
Authors: Waizenegger Irene C. , Baum Anke , Steurer Steffen , Stadtmüller Heinz , Bader Gerd , Schaaf Otmar , Garin-Chesa Pilar , Schlattl Andreas , Schweifer Norbert , Haslinger Christian , Colbatzky Florian , Mousa Sien , Kalkuhl Arno , Kraut Norbert , Adolf Günther R.
Published: April 2023

Legends for Supplementary Figures S1 - S6